US FDA Grants Orphan Drug Designation to CyGenica Limited for Innovative Glioblastoma Multiforme Treatment Drug Conjugate
Wednesday, September 13, 2023
CyGenica Limited, a dynamic biotechnology startup, has announced a significant milestone in the battle against Glioblastoma Multiforme (GBM), an aggressive form of brain cancer. Dr. Nusrat J M Sanghamitra, Co-founder and CEO of CyGenica, shared that the U.S. Food and Drug Administration (USFDA) has granted Orphan Drug Designation for their innovative drug conjugate developed for GBM treatment. This approval represents a major step forward for CyGenica's intracellular delivery platform, GEENIE, offering newfound hope to cancer patients and those suffering from rare diseases.
GBM remains a formidable challenge in the field of oncology, demanding innovative and effective treatment solutions. CyGenica's Orphan Drug Designation approval for their unique drug conjugate underscores their commitment to addressing the unmet medical needs of GBM patients.
This achievement signifies a pivotal moment in CyGenica's journey, marking the first application of their targeted intracellular delivery platform, GEENIE, for any disease indication. Beyond GBM, the company envisions a future where GEENIE drives the development of novel therapies for various cancers and rare diseases, including nucleotide-based treatments like antisense oligonucleotides, SiRNAs, and genome editing therapeutics.
Dr. Nusrat J M Sanghamitra expressed her enthusiasm, stating, We are incredibly pleased to receive USFDA approval for our Orphan Drug Designation in GBM treatment. This validation enables CyGenica to advance innovation and expand our intracellular delivery platform, GEENIE, to offer hope to countless patients.
As CyGenica progresses with its novel drug conjugate and GEENIE platform, the company actively seeks collaboration with biotech investors and pharmaceutical firms.
This presents a remarkable opportunity for potential partners to join us in the global fight against GBM, various cancer types, and rare diseases," emphasized Dr. Sanghamitra. "Together, we can harness the full potential of GEENIE and make a lasting impact on the lives of patients worldwide.
